Dr. Gainor Discusses the Future of EGFR+ NSCLC

Justin F. Gainor, MD
Published: Monday, Nov 27, 2017



Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer (NSCLC).

The results of FLAURA are convincing enough to suggest that osimertinib (Tagrisso) should be first-line treatment of choice for these patients, says Gainor.

Moving forward, better understanding response and resistance to osimertinib should be a priority, Gainor adds.


Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer (NSCLC).

The results of FLAURA are convincing enough to suggest that osimertinib (Tagrisso) should be first-line treatment of choice for these patients, says Gainor.

Moving forward, better understanding response and resistance to osimertinib should be a priority, Gainor adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x